Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5 CAR T Cells in Relapsed or Refractory T-Cell Malignancies
NCT06316856Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD5 CAR T cells in T-cell lymphoma (PTCL), T-cell acute lymphoblastic leukemia (T-ALL), acute lymphoblastic leukemia (ALL), sponsored by Beijing Gaobo Hospital. Started Jun 2024; status: recruiting.
02
Drugs
CD5 CAR T cells
03
Conditions
T-cell lymphoma (PTCL)T-cell acute lymphoblastic leukemia (T-ALL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06316856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316856.